{
    "clinical_study": {
        "@rank": "129694", 
        "brief_summary": {
            "textblock": "RATIONALE: The Chinese herb Scutellaria barbata contains ingredients that may slow the\n      growth of cancer cells and may be an effective treatment for metastatic breast cancer.\n\n      PURPOSE: Phase I/II trial to study the effectiveness of Scutellaria barbata in treating\n      women who have metastatic breast cancer."
        }, 
        "brief_title": "Herbal Therapy in Treating Women With Metastatic Breast Cancer", 
        "completion_date": {
            "#text": "April 2006", 
            "@type": "Actual"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the efficacy of Scutellaria barbata (Chinese herbal extract) in terms of\n           tumor response in women with metastatic breast cancer.\n\n        -  Determine the safety and toxicity of this therapy in these patients.\n\n        -  Determine the feasibility of this therapy in these patients.\n\n        -  Determine the time to progression, overall survival, and resource utilization of\n           patients treated with this therapy.\n\n        -  Determine the quality of life of patients treated with this therapy.\n\n        -  Determine the bioavailability and pharmacokinetics of this therapy in these patients.\n\n      OUTLINE: Patients receive oral Scutellaria barbata (Chinese herbal extract) twice daily for\n      12 months in the absence of disease progression or unacceptable toxicity.\n\n      Quality of life is assessed at baseline and then every 6 months thereafter.\n\n      PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed breast cancer (may include original primary cancer\n             diagnosis)\n\n          -  Measurable disease\n\n          -  Metastatic involvement with minimal or no symptoms\n\n               -  Solitary metastases require histological confirmation\n\n          -  No extensive liver involvement (more than 50% of liver parenchyma)\n\n          -  No lymphangitic pulmonary involvement\n\n          -  CNS involvement or spinal cord compression allowed if stabilized by therapy for more\n             than 3 months\n\n          -  Hormone receptor status:\n\n               -  Not specified\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Sex:\n\n          -  Female\n\n        Menopausal status:\n\n          -  Not specified\n\n        Performance status:\n\n          -  ECOG 0-1\n\n        Life expectancy:\n\n          -  More than 6 months\n\n        Hematopoietic:\n\n          -  WBC at least 2,500/mm^3\n\n          -  Platelet count at least 75,000/mm^3\n\n        Hepatic:\n\n          -  See Disease Characteristics\n\n          -  Bilirubin no greater than 1.7 mg/dL\n\n        Renal:\n\n          -  Creatinine no greater than 2.0 mg/dL\n\n        Other:\n\n          -  Not pregnant\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n          -  No history of multiple or severe food or medicine allergies\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  At least 1 week since prior biologic therapy\n\n          -  No concurrent anticancer biologic therapy\n\n        Chemotherapy:\n\n          -  At least 1 week since prior chemotherapy\n\n          -  No concurrent anticancer chemotherapy\n\n        Endocrine therapy:\n\n          -  At least 1 week since prior hormonal therapy\n\n          -  No concurrent anticancer hormonal therapy\n\n        Radiotherapy:\n\n          -  Not specified\n\n        Surgery:\n\n          -  Not specified\n\n        Other:\n\n          -  Recovered from prior anticancer therapy\n\n          -  At least 1 week since prior investigational agents\n\n          -  At least 1 week since prior herbal medications\n\n          -  No other concurrent anticancer therapy\n\n          -  No other concurrent investigational agents\n\n          -  Concurrent pamidronate allowed\n\n          -  Concurrent acupuncture or other nonherbal therapy allowed\n\n          -  Concurrent nutritional vitamin supplementation (up to 5 times recommended daily\n             allowance) allowed"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 4, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00028977", 
            "org_study_id": "CDR0000069155", 
            "secondary_id": [
                "UCSF-CRO-00758", 
                "UCSF-IND-59521", 
                "NCI-G01-2043"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "herba scutellaria barbata", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "herba scutellaria Barbatae (HSB)", 
                "intervention_type": "Other", 
                "other_name": "Traditional Chinese Medicine"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "stage IV breast cancer", 
            "recurrent breast cancer"
        ], 
        "lastchanged_date": "September 13, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/UCSF-CRO-00758"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "UCSF Comprehensive Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Plantation", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33324"
                    }, 
                    "name": "Cancer Research Network, Incorporated"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Pilot Safety, Feasibility, Efficacy And Correlative (Phase I/II) Study Assessing Herba Scutellaria Barbatae (HSB) For Metastatic Breast Cancer", 
        "overall_official": {
            "affiliation": "University of California, San Francisco", 
            "last_name": "Hope S. Rugo, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2006", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00028977"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of California, San Francisco", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of California, San Francisco", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2001", 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }, 
    "geocoordinates": {
        "Cancer Research Network, Incorporated": "26.128 -80.233", 
        "UCSF Comprehensive Cancer Center": "37.775 -122.419"
    }
}